Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2018: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2016: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
Outline of Final Research Achievements |
The inflammatory bowel disease is an intractable disease with chronic inflammation of the intestinal mucosa. Treg cells play an important role to suppress immune response-induced inflammation. In this study, we show that DNAM-1, an immunoreceptor expressed on Tregs, induces instability in the expression of Foxp3, a master regulator of Tregs, in the inflammatory environment and limits the immunosuppressive capacity of Tregs. Thus, DNAM-1 may be a good therapeutic target for the control of inflammatory bowel disease associated with Treg dysfunction.
|